A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Advanced Solid Cancer Clinical Trial

Official title:
A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS015 In Patients With Advanced Solid Tumors

Status Recruiting

Clinical Trial Summary

This is a Phase I open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of JS015 in patients with advanced solid tumors. The Recommended dose for phase II trial （RP2D） was determined based on the safety, pharmacokinetics, and initial efficacy data of the dose escalation and extension.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Solid Cancer

Clinical Trial Details

NCT number	NCT05770310
Study type	Interventional
Source	Shanghai Junshi Bioscience Co., Ltd.
Contact	Kai Xu, Project manager
Phone	+86 13761020175
Email	kai_xu@junshipharma.com
Status	Recruiting
Phase	Phase 1
Start date	February 1, 2023
Completion date	July 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01416623` - A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies	Phase 1
Recruiting	`NCT03618043` - Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer	Phase 1
Recruiting	`NCT03917043` - APG-2449 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT03884517` - Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer	Phase 1
Recruiting	`NCT03791112` - A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor	Phase 1
Recruiting	`NCT04877717` - A Study of SHR-A1904 in Patients With Advanced Solid Cancer	Phase 1
Recruiting	`NCT05947474` - ORB-011 In Patients With Advanced Solid Tumors	Phase 1